which is why this study without real comparator is called ph3b.
GILD has enough money to run countless studies and cover all the bases. One still has to wonder if this new Phase 3B study indicates a lack of confidence in their follow-up NS5A inhibitor GS-5816. If this drug is active in GT3 longer durations of Sofo/Riba will be an afterthought.
Market Data 
Markets 
AI
